

Maarten de Wit

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6428712/publications.pdf>

Version: 2024-02-01

115
papers

15,357
citations

76326

40
h-index

22166

113
g-index

118
all docs

118
docs citations

118
times ranked

11450
citing authors

#	ARTICLE	IF	CITATIONS
1	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 960-977.	0.9	3,366
2	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 685-699.	0.9	1,860
3	Treating rheumatoid arthritis to target: recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 631-637.	0.9	1,711
4	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 492-509.	0.9	1,688
5	American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 404-413.	0.9	657
6	EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 700.1-712.	0.9	609
7	Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 3-17.	0.9	484
8	A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1012-1019.	0.9	314
9	Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 952-957.	0.9	258
10	2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 8-13.	0.9	223
11	Patients and professionals as research partners: Challenges, practicalities, and benefits. <i>Arthritis and Rheumatism</i> , 2006, 55, 676-680.	6.7	214
12	Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 760-770.	0.9	205
13	International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 673-680.	0.9	194
14	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. <i>Nature Reviews Rheumatology</i> , 2022, 18, 465-479.	8.0	182
15	Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 965-973.	0.9	179
16	Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 744-759.	0.9	167
17	Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 71-87.	0.9	158
18	Involving patient research partners has a significant impact on outcomes research: a responsive evaluation of the international OMERACT conferences. <i>BMJ Open</i> , 2013, 3, e002241.	1.9	145

#	ARTICLE	IF	CITATIONS
19	Emerging Guidelines for Patient Engagement in Research. <i>Value in Health</i> , 2017, 20, 481-486.	0.3	144
20	Psoriatic arthritis. <i>Nature Reviews Disease Primers</i> , 2021, 7, 59.	30.5	113
21	Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 778-786.	0.9	104
22	Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 482-492.	0.9	102
23	Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 490-498.	0.9	98
24	OMERACT Filter 2.1: Elaboration of the Conceptual Framework for Outcome Measurement in Health Intervention Studies. <i>Journal of Rheumatology</i> , 2019, 46, 1021-1027.	2.0	97
25	Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016. <i>Journal of Rheumatology</i> , 2017, 44, 1522-1528.	2.0	93
26	Suppressing Inflammation in Rheumatoid Arthritis: Does Patient Global Assessment Blur the Target? A Practice-Based Call for a Paradigm Change. <i>Arthritis Care and Research</i> , 2018, 70, 369-378.	3.4	84
27	The OMERACT-OARSI Core Domain Set for Measurement in Clinical Trials of Hip and/or Knee Osteoarthritis. <i>Journal of Rheumatology</i> , 2019, 46, 981-989.	2.0	82
28	Drivers of patient global assessment in patients with rheumatoid arthritis who are close to remission: an analysis of 1588 patients. <i>Rheumatology</i> , 2017, 56, 1573-1578.	1.9	71
29	The Delphi method "more research please". <i>Journal of Clinical Epidemiology</i> , 2019, 106, 136-139.	5.0	71
30	Core Domain Set Selection According to OMERACT Filter 2.1: The OMERACT Methodology. <i>Journal of Rheumatology</i> , 2019, 46, 1014-1020.	2.0	65
31	Instrument Selection Using the OMERACT Filter 2.1: The OMERACT Methodology. <i>Journal of Rheumatology</i> , 2019, 46, 1028-1035.	2.0	61
32	Comparing patient-perceived and physician-perceived remission and low disease activity in psoriatic arthritis: an analysis of 410 patients from 14 countries. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 201-208.	0.9	59
33	Determinants of Patient-Physician Discordance in Global Assessment in Psoriatic Arthritis: A Multicenter European Study. <i>Arthritis Care and Research</i> , 2017, 69, 1606-1611.	3.4	58
34	Updating the OMERACT Filter: Implications for Patient-reported Outcomes. <i>Journal of Rheumatology</i> , 2014, 41, 1011-1015.	2.0	54
35	A systematic review of measurement properties of patient reported outcome measures in psoriatic arthritis: A GRAPPA-OMERACT initiative. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 47, 654-665.	3.4	50
36	Fatigue in psoriatic arthritis: A cross-sectional study of 246 patients from 13 countries. <i>Joint Bone Spine</i> , 2016, 83, 439-443.	1.6	47

#	ARTICLE	IF	CITATIONS
37	Practical guidance for engaging patients in health research, treatment guidelines and regulatory processes: results of an expert group meeting organized by the World Health Organization (WHO) and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). <i>Aging Clinical and Experimental Research</i> , 2019, 31, 905-915.	2.9	47
38	Recommendations for the Involvement of Patient Research Partners (PRP) in OMERACT Working Groups. A Report from the OMERACT 2014 Working Group on PRP. <i>Journal of Rheumatology</i> , 2016, 43, 187-193.	2.0	46
39	PsAID12 Provisionally Endorsed at OMERACT 2018 as Core Outcome Measure to Assess Psoriatic Arthritis-specific Health-related Quality of Life in Clinical Trials. <i>Journal of Rheumatology</i> , 2019, 46, 990-995.	2.0	43
40	International Consortium for Health Outcome Measurement Set of Outcomes That Matter to People Living With Inflammatory Arthritis: Consensus From an International Working Group. <i>Arthritis Care and Research</i> , 2019, 71, 1556-1565.	3.4	43
41	Defining Outcome Measures for Psoriatic Arthritis: A Report from the GRAPPA-OMERACT Working Group. <i>Journal of Rheumatology</i> , 2017, 44, 697-700.	2.0	42
42	Testing different thresholds for patient global assessment in defining remission for rheumatoid arthritis: are the current ACR/EULAR Boolean criteria optimal?. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 445-452.	0.9	42
43	Successful Stepwise Development of Patient Research Partnership: 14 Years' Experience of Actions and Consequences in Outcome Measures in Rheumatology (OMERACT). <i>Patient</i> , 2017, 10, 141-152.	2.7	41
44	Safety and efficacy of faecal microbiota transplantation for active peripheral psoriatic arthritis: an exploratory randomised placebo-controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1158-1167.	0.9	40
45	Determinants of Patient-Reported Psoriatic Arthritis Impact of Disease: An Analysis of the Association With Sex in 458 Patients From Fourteen Countries. <i>Arthritis Care and Research</i> , 2020, 72, 1772-1779.	3.4	39
46	Endorsement of the 66/68 Joint Count for the Measurement of Musculoskeletal Disease Activity: OMERACT 2018 Psoriatic Arthritis Workshop Report. <i>Journal of Rheumatology</i> , 2019, 46, 996-1005.	2.0	36
47	Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research. <i>RMD Open</i> , 2020, 6, e001374.	3.8	36
48	Systematic literature review of domains assessed in psoriatic arthritis to inform the update of the psoriatic arthritis core domain set. <i>RMD Open</i> , 2016, 2, e000217.	3.8	35
49	Dual target strategy: a proposal to mitigate the risk of overtreatment and enhance patient satisfaction in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e109-e109.	0.9	35
50	Patient Involvement in Outcome Measures for Psoriatic Arthritis. <i>Current Rheumatology Reports</i> , 2014, 16, 418.	4.7	34
51	Preparing researchers for patient and public involvement in scientific research: Development of a hands-on learning approach through action research. <i>Health Expectations</i> , 2018, 21, 752-763.	2.6	34
52	Response to: "Comment on: "EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update" by Gossec et al" by Wei et al. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e139-e139.	0.9	30
53	Facilitating and inhibiting factors for long-term involvement of patients at outcome conferences: lessons learnt from a decade of collaboration in OMERACT: a qualitative study. <i>BMJ Open</i> , 2013, 3, e003311.	1.9	27
54	Practical guidance for patient-centred health research. <i>Lancet</i> , The, 2019, 393, 1095-1096.	13.7	27

#	ARTICLE	IF	CITATIONS
55	“They Are Talking About Me, but Not with Me” A Focus Group Study to Explore the Patient Perspective on Interprofessional Team Meetings in Primary Care. <i>Patient</i> , 2017, 10, 429-438.	2.7	26
56	Uptake of the OMERACT-OARSI Hip and Knee Osteoarthritis Core Outcome Set: Review of Randomized Controlled Trials from 1997 to 2017. <i>Journal of Rheumatology</i> , 2019, 46, 976-980.	2.0	25
57	Outcome Measures in Rheumatology - Interventions for medication Adherence (OMERACT-Adherence) Core Domain Set for Trials of Interventions for Medication Adherence in Rheumatology: 5 Phase Study Protocol. <i>Trials</i> , 2018, 19, 204.	1.6	23
58	Development of a Draft Core Set of Domains for Measuring Shared Decision Making in Osteoarthritis: An OMERACT Working Group on Shared Decision Making. <i>Journal of Rheumatology</i> , 2015, 42, 2442-2447.	2.0	22
59	Toward Ensuring Health Equity: Readability and Cultural Equivalence of OMERACT Patient-reported Outcome Measures. <i>Journal of Rheumatology</i> , 2015, 42, 2448-2459.	2.0	21
60	Toward the Development of a Core Set of Outcome Domains to Assess Shared Decision-making Interventions in Rheumatology: Results from an OMERACT Delphi Survey and Consensus Meeting. <i>Journal of Rheumatology</i> , 2017, 44, 1544-1550.	2.0	21
61	Consensus Building in OMERACT: Recommendations for Use of the Delphi for Core Outcome Set Development. <i>Journal of Rheumatology</i> , 2019, 46, 1041-1046.	2.0	21
62	Patient and Caregiver Priorities for Medication Adherence in Gout, Osteoporosis, and Rheumatoid Arthritis: Nominal Group Technique. <i>Arthritis Care and Research</i> , 2020, 72, 1410-1419.	3.4	19
63	Addressing Health Literacy Needs in Rheumatology: Which Patient Health Literacy Profiles Need the Attention of Health Professionals?. <i>Arthritis Care and Research</i> , 2021, 73, 100-109.	3.4	19
64	Improving domain definition and outcome instrument selection: Lessons learned for OMERACT from imaging. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1125-1133.	3.4	18
65	Unique role of rheumatology in establishing collaborative relationships in research. Past, present and future of patient engagement. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 293-296.	0.9	17
66	Health technology assessment: a framework. <i>RMD Open</i> , 2020, 6, e001289.	3.8	17
67	Validating Rheumatoid Arthritis Remission Using the Patients’ Perspective: Results from a Special Interest Group at OMERACT 2016. <i>Journal of Rheumatology</i> , 2017, 44, 1889-1893.	2.0	15
68	Scope of Outcomes in Trials and Observational Studies of Interventions Targeting Medication Adherence in Rheumatic Conditions: A Systematic Review. <i>Journal of Rheumatology</i> , 2020, 47, 1565-1574.	2.0	15
69	OMERACT Development of a Core Domain Set of Outcomes for Shared Decision-making Interventions. <i>Journal of Rheumatology</i> , 2019, 46, 1409-1414.	2.0	14
70	Response to: “Correspondence on EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update” by Fallon et al. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e174-e174.	0.9	14
71	Determinants of sleep impairment in psoriatic arthritis: An observational study with 396 patients from 14 countries. <i>Joint Bone Spine</i> , 2020, 87, 449-454.	1.6	14
72	The GRAPPA-OMERACT Psoriatic Arthritis Working Group at the 2018 Annual Meeting: Report and Plan for Completing the Core Outcome Measurement Set. <i>Journal of Rheumatology</i> , 2019, 95, 33-37.	2.0	14

#	ARTICLE	IF	CITATIONS
73	Identifying potential barriers and solutions to patient partner compensation (payment) in research. <i>Research Involvement and Engagement</i> , 2022, 8, 7.	2.9	14
74	Phrasing of the patient global assessment in the rheumatoid arthritis ACR/EULAR remission criteria: an analysis of 967 patients from two databases of early and established rheumatoid arthritis patients. <i>Clinical Rheumatology</i> , 2018, 37, 1503-1510.	2.2	13
75	Endorsement of the OMERACT core domain set for shared decision making interventions in rheumatology trials: Results from a multi-stepped consensus-building approach. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 593-600.	3.4	13
76	Comparing the Patient-Reported Physical Function Outcome Measures in a Real-Life International Cohort of Patients With Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2021, 73, 593-602.	3.4	12
77	EULAR points to consider when analysing and reporting comparative effectiveness research using observational data in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 780-785.	0.9	12
78	Identifying Provisional Generic Contextual Factor Domains for Clinical Trials in Rheumatology: Results from an OMERACT Initiative. <i>Journal of Rheumatology</i> , 2019, 46, 1159-1163.	2.0	11
79	Cost assessment of health interventions and diseases. <i>RMD Open</i> , 2020, 6, e001287.	3.8	11
80	EULAR/eumusc.net standards of care for rheumatoid arthritis: cross-sectional analyses of importance, level of implementation and care gaps experienced by patients and rheumatologists across 35 European countries. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1423-1431.	0.9	11
81	Residual Disease Associated with Suboptimal Treatment Response in Patients with Psoriatic Arthritis: A Systematic Review of Real-World Evidence. <i>Rheumatology and Therapy</i> , 2022, 9, 803-821.	2.3	11
82	Be an ambassador for change that you would like to see, a call to action to all stakeholders for co-creation in healthcare and medical research to improve quality of life of people with a neuromuscular disease. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, 126.	2.7	10
83	Validity and reliability of the EULAR instrument RAID.7 as a tool to assess individual domains of impact of disease in rheumatoid arthritis: a cross-sectional study of 671 patients. <i>RMD Open</i> , 2021, 7, e001539.	3.8	10
84	Content and Face Validity and Feasibility of 5 Candidate Instruments for Psoriatic Arthritis Randomized Controlled Trials: The PsA OMERACT Core Set Workshop at the GRAPPA 2017 Annual Meeting. <i>Journal of Rheumatology</i> , 2018, 94, 17-25.	2.0	10
85	Facilitators to implement standards of care for rheumatoid arthritis and osteoarthritis: the EUMUSC.NET project. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1545-1548.	0.9	9
86	Building Bridges between Researchers and Patient Research Partners: A Report from the GRAPPA 2014 Annual Meeting. <i>Journal of Rheumatology</i> , 2015, 42, 1021-1026.	2.0	9
87	Patient perspective in outcome measures developed by OMERACT. <i>Indian Journal of Rheumatology</i> , 2013, 8, S17-S22.	0.4	8
88	Improving Benefit-harm Assessment of Therapies from the Patient Perspective: OMERACT Premeeting Toward Consensus on Core Sets for Randomized Controlled Trials. <i>Journal of Rheumatology</i> , 2019, 46, 1053-1058.	2.0	8
89	Experiences and perceptions of patients with psoriatic arthritis participating in a trial of faecal microbiota transplantation: a nested qualitative study. <i>BMJ Open</i> , 2021, 11, e039471.	1.9	8
90	Considerations and priorities for incorporating the patient perspective on remission in rheumatoid arthritis: An OMERACT 2020 special interest group report. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1108-1112.	3.4	8

#	ARTICLE	IF	CITATIONS
91	Patients with rheumatoid arthritis facing sick leave or work disability meet varying regulations: a study among rheumatologists and patients from 44 European countries. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1472-1479.	0.9	7
92	Evidence for Psoriatic Arthritis Impact of Disease (PsAID12) as Core Instrument to Measure Health-Related Quality of Life in Psoriatic Arthritis: A Systematic Review of Psychometric Properties. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2020, 5, 12-22.	0.7	7
93	OMERACT consensus-based operational definition of contextual factors in rheumatology clinical trials: A mixed methods study. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 601-606.	3.4	7
94	Development of a standard form for assessing research grant applications from the perspective of patients. <i>Research Involvement and Engagement</i> , 2018, 4, 27.	2.9	6
95	Towards consensus in defining and handling contextual factors within rheumatology trials: an initial qualitative study from an OMERACT working group. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 242-249.	0.9	6
96	Addressing Challenges in Developing a Core Domain Set in Adherence Interventions in Rheumatology: A Report from the OMERACT-Adherence Group. <i>Journal of Rheumatology</i> , 2019, 46, 1202-1206.	2.0	5
97	Steps in implementing a health economic evaluation. <i>RMD Open</i> , 2020, 6, e001288.	3.8	5
98	Trial Characteristics as Contextual Factors When Evaluating Targeted Therapies in Patients With Psoriatic Disease: A Meta-€Epidemiologic Study. <i>Arthritis Care and Research</i> , 2018, 70, 1206-1217.	3.4	4
99	What€influences patients€™ opinion of remission and low disease activity in psoriatic arthritis? Principal component analysis of an international study. <i>Rheumatology</i> , 2021, 60, 5292-5299.	1.9	4
100	Analysing and reporting of observational data: a systematic review informing the EULAR points to consider when analysing and reporting comparative effectiveness research with observational data in rheumatology. <i>RMD Open</i> , 2021, 7, e001818.	3.8	4
101	Patient engagement in health technology assessment (HTA) and the regulatory process: what about rheumatology?. <i>RMD Open</i> , 2020, 6, e001286.	3.8	4
102	Disparities in healthcare in psoriatic arthritis: an analysis of 439 patients from 13 countries. <i>RMD Open</i> , 2022, 8, e002031.	3.8	4
103	Population characteristics as important contextual factors in rheumatological trials: an exploratory meta-epidemiological study from an OMERACT Working Group. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1269-1276.	0.9	3
104	Residual patient-reported burden in 444 patients with psoriatic arthritis in remission or low disease: a cross-sectional analysis. <i>Joint Bone Spine</i> , 2022, , 105372.	1.6	3
105	Exploring discordance between Health Literacy Questionnaire scores of people with RMDs and assessment by treating health professionals. <i>Rheumatology</i> , 2022, 62, 52-64.	1.9	3
106	What have we learned from a decade of patient involvement in OMERACT and its effect on trial outcome assessments?. <i>Trials</i> , 2011, 12, .	1.6	2
107	Pain Measurement in Rheumatic and Musculoskeletal Diseases: Where To Go from Here? Report from a Special Interest Group at OMERACT 2018. <i>Journal of Rheumatology</i> , 2019, 46, 1355-1359.	2.0	2
108	Instruments Measuring Physical Function for Psoriatic Arthritis Endorsed at GRAPPA 2020 Annual Meeting: Updates of the GRAPPA-OMERACT Working Group. <i>Journal of Rheumatology</i> , 2021, , jrheum.201679.	2.0	2

#	ARTICLE	IF	CITATIONS
109	Response to: "Increasing the threshold for patient global assessment in defining remission may have a different impact in patients with early and established rheumatoid arthritis" by Bugatti et al. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e56-e56.	0.9	1
110	Researchers' perspectives on methodological challenges and outcomes selection in interventional studies targeting medication adherence in rheumatic diseases: an OMERACT-adherence study. <i>BMC Rheumatology</i> , 2021, 5, 26.	1.6	1
111	Patient engagement in health technology assessment (HTA) and the regulatory process: what about rheumatology?. <i>RMD Open</i> , 2020, 6, .	3.8	1
112	The eumusc.net standards of care for rheumatoid arthritis: importance and current implementation according to patients and healthcare providers in the Netherlands. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 275-283.	0.8	1
113	Patient Experienced Symptom State in rheumatoid arthritis: sensitivity to change in disease activity and impact. <i>Rheumatology</i> , 2022, 62, 98-107.	1.9	1
114	Comment on: "It can't be zero!" difficulties in completing patient global assessment in rheumatoid arthritis: a mixed methods study: reply. <i>Rheumatology</i> , 2021, 60, e30-e31.	1.9	0
115	Patient Perspectives on Outcome Domains of Medication Adherence Trials in Inflammatory Arthritis: An International OMERACT Focus Group Study. <i>Journal of Rheumatology</i> , 2021, 48, 1480-1487.	2.0	0